RT Journal Article
SR Electronic
T1 First-in-Human PET Imaging and Estimated Radiation Dosimetry of <span class="sc">l</span>-[5-<sup>11</sup>C]-Glutamine in Patients with Metastatic Colorectal Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 36
OP 43
DO 10.2967/jnumed.120.261594
VO 63
IS 1
A1 Allison S. Cohen
A1 Joe Grudzinski
A1 Gary T. Smith
A1 Todd E. Peterson
A1 Jennifer G. Whisenant
A1 Tiffany L. Hickman
A1 Kristen K. Ciombor
A1 Dana Cardin
A1 Cathy Eng
A1 Laura W. Goff
A1 Satya Das
A1 Robert J. Coffey
A1 Jordan D. Berlin
A1 H. Charles Manning
YR 2022
UL http://jnm.snmjournals.org/content/63/1/36.abstract
AB Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Noninvasive imaging via PET may help facilitate precision treatment of cancer through patient selection and monitoring of treatment response. l-[5-11C]-glutamine (11C-glutamine) is a PET tracer designed to study glutamine uptake and metabolism. The aim of this first-in-human study was to evaluate the radiologic safety and biodistribution of 11C-glutamine for oncologic PET imaging. Methods: Nine patients with confirmed metastatic colorectal cancer underwent PET/CT imaging. Patients received 337.97 ± 44.08 MBq of 11C-glutamine. Dynamic PET acquisitions that were centered over the abdomen or thorax were initiated simultaneously with intravenous tracer administration. After the dynamic acquisition, a whole-body PET/CT scan was acquired. Volume-of-interest analyses were performed to obtain estimates of organ-based absorbed doses of radiation. Results: 11C-glutamine was well tolerated in all patients, with no observed safety concerns. The organs with the highest radiation exposure included the bladder, pancreas, and liver. The estimated effective dose was 4.46E−03 ± 7.67E−04 mSv/MBq. Accumulation of 11C-glutamine was elevated and visualized in lung, brain, bone, and liver metastases, suggesting utility for cancer imaging. Conclusion: PET using 11C-glutamine appears safe for human use and allows noninvasive visualization of metastatic colon cancer lesions in multiple organs. Further studies are needed to elucidate its potential for other cancers and for monitoring response to treatment.